A phase II study of perioperative CapeOx for clinical SS/SE N1-3 M0 gastric cancer (OGSG1601) cSS/SE N1-3 M0 胃癌に対する周術期capecitabine plus oxaliplatin (CapeOx)療法の第II相試験(OGSG1601)

既治療進行・再発胃癌患者に対する減量投与nab-Paclitaxel のPII試験(OGSG1302)

HER2陰性再発・進行胃癌に対するSP療法とXP療法との比較： HERBIS-2 (OGSG 1103)試験とHERBIS-4A (OGSG 1105)試験との統合解析

根治切除可能な大型3型 / 4型胃癌に対する術前TS-1＋CDDP併用化学放射線療法 第I/II相臨床試験（OGSG1205）

Comparison of S-1–cisplatin every 5 weeks with capecitabine-cisplatin every 3 weeks for HER2-negative gastric cancer (recurrent after S-1 adjuvant therapy or chemotherapy-naïve advanced): pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials

Comparison of S‑1–cisplatin every 5 weeks with capecitabine‑cisplatin every 3 weeks for HER2‑negative gastric cancer (recurrent after S‑1 adjuvant therapy or chemotherapy‑naïve advanced): pooled analysis of HERBIS‑2 (OGSG 1103) and HERBIS‑4A (OGSG 1105) trials

Docetaxel plus S‑1 versus cisplatin plus S‑1 in unresectable gastric cancer without measurable lesions: a randomized phase II trial (HERBIS‑3)

Phase II Study of Panitumumab Monotherapy in Chemotherapy- Naive Frail or Elderly Patients with Unresectable RAS Wild-Type Colorectal Cancer OGSG 1602

高度リンパ節転移を伴う進行胃癌に対する術前カペシタビン＋ シスプラチン療法第Ⅱ相臨床試験（OGSG1401)

A phase II trial of dose‑reduced nab‑paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302)